Minerva Surgical (Minerva Surgical) Cash, Cash Equivalents, Marketable Securities : $11.13 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical Cash, Cash Equivalents, Marketable Securities?

Minerva Surgical's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 ($25.26 Mil) to Jun. 2023 ($15.71 Mil) but then stayed the same from Jun. 2023 ($15.71 Mil) to Sep. 2023 ($11.13 Mil).

Minerva Surgical's annual cash, cash equivalents, marketable securities increased from Dec. 2020 ($17.36 Mil) to Dec. 2021 ($40.61 Mil) but then declined from Dec. 2021 ($40.61 Mil) to Dec. 2022 ($6.94 Mil).

Minerva Surgical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Minerva Surgical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Surgical Cash, Cash Equivalents, Marketable Securities Chart

Minerva Surgical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

27.09

17.36

40.61

6.94

Minerva Surgical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial										15.11	6.94	25.26	15.71	11.13

Minerva Surgical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Minerva Surgical (OTCPK:UTRS) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Minerva Surgical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Surgical (Minerva Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

4255 Burton Drive, Santa Clara, CA, USA, 95054

Website

https://www.minervasurgical.com

Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.

Executives

Daniel Cohen	director	C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger	director, 10 percent owner	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen	director, officer: Chief Executive Officer	C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper	director, officer: President and CEO	3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi	officer: VP Medical Affairs	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux	officer: COO	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung	officer: CFO	1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt	director	SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson	director	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202